Internal Medicine CME

In this online, self-learning activity:

Dravet syndrome (DS) is a rare form of early-onset epilepsy syndrome affecting between 1:16,000 and 1:46,000 and is associated with pleomorphic seizure activity, cognitive decline, motor, and behavior abnormalities. Sudden unexpected death in epilepsy is the cause of death in nearly half of the deaths in patients with DS, with the mean age of death 8.7 years old and 73% of deaths occurring before age 10. Seizures typically begin in the first year of age, with most occurring between months 5 and 8, and it is usually a prolonged, tonic-clonic (accounting for 52% of first seizures) or hemiclonic (35%) seizure. Environmental triggers or events, such as fever, acute stress, and physical exercise may precipitate seizures, and at least 85% of those who are clinically diagnosed with DS have variations in the SCN1A gene. Unfortunately, diagnosis is not uncommonly delayed until a patient 3 years of age or older, prior to which antiseizure medication selection may be suboptimal or ineffective, which may lead to seizure exacerbation, an increased risk of status epilepticus, and worse cognitive outcomes.

The course introduces the reader to the endocannabinoid system and its interaction with the components of the cannabis plant, and addresses various aspects of medical marijuana, including administration, therapeutic use, drug metabolism, physiologic and cognitive effects, potential risks, and drug interactions.

The use of marijuana in obstetric patients, pediatric patients, adolescent patients and elderly patients is discussed in detail. Important considerations for patients with ischemic heart disease, hepatic disease, psychotic illness, and those with a history of drug dependence are also provided.

CBD in Clinical Care provides information that will assist clinicians in effectively treating and counseling cannabidiol (CBD) consumers. The physiological effects of CBD, CBD drug interactions, CBD’s side effects, and the conditions for which CBD has been shown by evidence-based clinical studies to be efficacious are all discussed in this course.

The New York Medical Cannabis Program Required Course Bundle has been approved by the New York State Office of Cannabis Management and satisfies the New York educational requirements to become a practitioner with the New York Medical Cannabis Program.

This bundle introduces the reader to the endocannabinoid system and its interaction with the components of the cannabis plant, and addresses various aspects of medical marijuana, including administration, therapeutic use, drug metabolism, physiologic and cognitive effects, potential risks, and drug interactions.

The use of marijuana in obstetric patients, pediatric patients, adolescent patients and elderly patients is discussed in detail. Important considerations for patients with ischemic heart disease, hepatic disease, psychotic illness, and those with a history of drug dependence are provided.

The New York State Medical Cannabis Program Rules and Regulations are outlined in a state-specific course, as well.

The Ohio Healthcare Provider Medical Marijuana Course Bundle for Certification (or maintenance of the CTR) is certified by the Ohio State Medical Association and satisfies the CME requirements for the initial Ohio Certificate to Recommend (CTR) application or for maintenance of the CTR.

This bundle introduces the reader to the endocannabinoid system and its interaction with the components of the cannabis plant, and addresses various aspects of medical marijuana, including administration, therapeutic use, drug metabolism, physiologic and cognitive effects, potential risks, and drug interactions.

The use of marijuana in obstetric patients, pediatric patients, adolescent patients and elderly patients is discussed in detail. Important considerations for patients with ischemic heart disease, hepatic disease, psychotic illness, and those with a history of drug dependence are provided.

The Ohio Medical Marijuana Control Program rules and regulations are outlined in a state-specific course, as well.

The Pennsylvania Medical Marijuana Program Required Course Bundle has been approved by the Pennsylvania Department of Health and satisfies the Pennsylvania educational requirements to become a practitioner with the Pennsylvania Medical Marijuana Program.

This bundle introduces the reader to the endocannabinoid system and its interaction with the components of the cannabis plant, and addresses various aspects of medical marijuana, including administration, therapeutic use, drug metabolism, physiologic and cognitive effects, potential risks, and drug interactions.

The use of marijuana in obstetric patients, pediatric patients, adolescent patients and elderly patients is discussed in detail. Important considerations for patients with ischemic heart disease, hepatic disease, psychotic illness, and those with a history of drug dependence are provided.

This course bundle also addresses the use of cannabidiol (CBD) in clinical care, and the information will assist clinicians in effectively treating and counseling CBD consumers. The physiological effects of CBD, CBD drug interactions, CBD’s side effects, and the conditions for which CBD has been shown by evidence-based clinical studies to be efficacious are all discussed in this course bundle.

The Pennsylvania Medical Marijuana Program rules and regulations are outlined in a state-specific course, as well.

The Utah Medical Cannabis Program Required Course Bundle has been approved by the Utah Department of Health and satisfies the Utah educational requirements to become a practitioner with the Utah Medical Cannabis Program.

The Utah Medical Cannabis Program Required Course Bundle introduces the reader to the endocannabinoid system and its interaction with the components of the cannabis plant, and addresses administration, therapeutic use, drug metabolism, physiologic and cognitive effects, potential risks, and drug interactions.

The use of marijuana in obstetric patients, pediatric patients, adolescent patients and elderly patients is discussed in detail. Important considerations for patients with ischemic heart disease, hepatic disease, psychotic illness, and those with a history of drug dependence are provided.

This course bundle also provides information that assists clinicians in effectively treating and counseling CBD consumers.

The West Virginia Medical Cannabis Program Required Course Bundle has been approved by the West Virginia Department of Health and Human Resources, Bureau for Public Health, Office of Medical Cannabis and satisfies the West Virginia educational requirements to become a practitioner with the West Virginia Medical Cannabis Program.

This course introduces the reader to the endocannabinoid system and its interaction with the components of the cannabis plant, and addresses administration, therapeutic use, drug metabolism, physiologic and cognitive effects, potential risks, and drug interactions.

The use of marijuana in obstetric patients, pediatric patients, adolescent patients and elderly patients is discussed in detail. Important considerations for patients with ischemic heart disease, hepatic disease, psychotic illness, and those with a history of drug dependence are provided.

This course bundle also addresses the use of cannabidiol (CBD) in clinical care, and the information will assist clinicians in effectively treating and counseling CBD consumers. The physiological effects of CBD, CBD drug interactions, CBD’s side effects, and the conditions for which CBD has been shown by evidence-based clinical studies to be efficacious are all discussed in this course bundle.

The West Virginia medical cannabis program rules and regulations are outlined in a state-specific course, as well.

Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is a demyelinating, autoimmune condition affecting the central nervous system. MOGAD is characterized by the presence of autoantibodies directed against the MOG protein located on the surface of myelin sheaths surrounding nerve fibers in the CNS. The disease course may be monophasic or relapsing, and a progressive course is extremely rare, making the mortality rate fairly low (2.1%) compared to other neuroinflammatory diseases. It is a relatively new addition to the category of demyelinating diseases, and approximately 10,000 cases of MOGAD are estimated within the U.S.

GIBLIB is an on-demand streaming medical education platform where physicians and advanced practice providers go to learn and earn CME through convenient, high-quality educational content created by trusted experts from the world’s top hospitals.

With this purchase, you get a 1-year subscription to GIBLIB and the following features:

• Earn unlimited AMA PRA Category 1 Credits™
• Full library access to thousands of videos across all specialties
• Personalized and curated video recommendations
• Cross-device viewing on web and iOS
• New content released and available every week
• Create custom playlists that you can personally curate
• Bookmark videos for later viewing
• Take notes on specific content and review for later
• View transcripts of all videos, available in multiple languages

The management of critically ill patients with liver disease requires the expertise of a variety of healthcare providers from multiple disciplines. Cleveland Clinic addresses their multifaceted educational needs with the Interprofessional Approach to Liver Disease. Physicians, nurses and physician assistants will benefit from the latest strategies and evidence based management guidance from an expert faculty. Worth 14 AMA PRA Category I Credits™, with ANCC and AAPA accreditation provided as well. This enduring material also qualifies for 14 ABIM MOC points, with NO POST TEST.

Activity Description / Statement of Need:

In this online, self-learning activity:

Alpha 1-antitrypsin deficiency (AATD), characterized by misfolded and lower function of the serine protease inhibitor alpha-1 antitrypsin (AAT), is a genetic disorder resulting in the degradation of lung structures. Reduced levels of AAT result in overactivity of neutrophil elastase, which destroys connectivetissue within the lung and causes degradation of alveoli, reduced pulmonary elastic recoil, and airflow. Breakdown of the alveoli eventually manifest as chronic obstructive lung disease (COPD), and otherassociated complications include liver disease, which occurs in about ten percent of patients with AATD.The most common cause of death in patients with severe AATD is respiratory failure, which accounts for45 to 72% of deaths.

Target Audience:

The following HCPs: pulmonologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in pulmonology and internal medicine; and any other healthcare professionals with an interest in or who clinically encounter patients with AATD.